The Efficacy and Safety of Monoclonal Antibody Treatments Against COVID-19: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Abstract
Background: The use of monoclonal antibody as the proposed treatment of COVID-19 showed different results in various prior studies, and Efficacy remains open in literature. This study aimed to comprehensively determine the effect of monoclonal antibodies on clinical, laboratory, and safety outcomes in COVID-19 patients. Methods: Sixteen RCTs were analyzed in this meta-analysis using RevMan 5.4 to measure the pooled estimates of risk ratios (RRs) and standardized mean differences (SMDs) with 95% CIs. Results: The pooled effect of Monoclonal antibodies demonstrated efficacy on mortality risk reduction (RR=0,89 (95%CI 0.82-0.96), I2=13%, fixed-effect), Tocilizumab also show efficacy on mortality risk reduction for severe-critical disease (RR=0.90 (95%CI 0.83-0.97), I2=12%, fixed-effect)), need for mechanical ventilation (RR=0.76 (95%CI 0.62-0.94), I2=42%, random-effects), and hospital discharge (RR=1.07 (95%CI 1.00-1.14), I2=60%, random-effects). Bamlanivimab monotherapy did not reduce viral load (SMD=-0.07 (95%CI -0.21-0.07), I2=44%, fixed-effect). Monoclonal antibodies did not differ from placebo/standard therapy for hospital discharge at day 28-30 (RR=1.05 (95%CI 0.99–1.12), I2=71%, random-effects) and safety (RR=1.04 (95%CI 0.76–1.43), I2=54%, random-effects). Conclusion: Tocilizumab should be used for severe to critical COVID-19 because it is not harmful and can improve mortality risk, mechanical ventilation, and hospital discharge. Bamlanivimab-Etesevimab and REGN-COV2 reduced viral load in mild-moderate outpatients.
Keywords
References
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel Coronavirus–infected pneumonia. New England Journal of Medicine 2020;382(13):1199-207.
Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology 2021;19(3):141-54.
Hertanto DM, Sutanto H, Kencono-Wungu CD. Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future. Preprints 2021;2021040022.
Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect 2020;53(3):404-12.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;14(1):69-71.
Walls A, Park Y, Tortorici M, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281-92.e6.
Zhang C, Wu Z, Li JW, et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954.
Zhang S, Li L, Shen A, et al. Rational use of Tocilizumab in the treatment of novel Coronavirus pneumonia. Clin Drug Investig. 2020;40(6):511-8.
Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020;55(6):105982.
Carvelli J, Demaria O, Vély F, et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature. 2020;588(7836):146-50.
Woodruff T, Shukla A. The complement C5a-C5aR1 GPCR axis in COVID-19 therapeutics. Trends in Immunology. 2020;41(11):965-7.
U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: November 9, 2020. Food and drug administration. 2020 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-november-9-2020. (Accessed 2 February 2021).
Lipman N, Jackson L, Trudel L, et al. Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources. ILAR Journal 2005;46(3):258-68.
Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. British Journal of Pharmacology 2009;157(2):220-33.
Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020;9(1):382-385.
Yang L, Liu W, Yu X, et al. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Therapeutics 2020;3(3):205-212.
Patel S, Saxena B, Mehta P. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon. 2021;7(2):e06158.
Sterne J, Murthy S, Diaz J, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: A meta-analysis. JAMA. 2020;324(13):1330-41.
Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36-44.
Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically Ill patients with COVID-19. N Engl J Med 2021;384(16):1491-502.
Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern Med. 2021;181(1):32-40.
Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021.
Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med 2021;384(16):1503-16.
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med 2021;384(1):20-30.
Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med 2021;181(1):24-31.
Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med 2021;9(5):511-21.
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020;383(24):2333-44.
Veiga VC, Prats JAG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 2021;372:n84.
Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomed Pharmacother. 2021;133:110825.
Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021;5:522-32.
Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med 2021;384(3):229-37.
Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial. JAMA. 2021;325(7):632-644.
Lundgren JD, Grund B, Barkauskas CE, et al. A Neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med. 2021;384(10):905-914.
Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. N Engl J Med. 2021;384(3):238-51.
Vlaar APJ, de Bruin S, Busch M, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020;12:764-73.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Aziz M, Haghbin H, Abu Sitta E, et al. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. J Med Virol. 2021;93(3):1620-30.
Kotak S, Khatri M, Malik M, et al. Use of Tocilizumab in COVID-19: A systematic review and meta-analysis of current evidence. Cureus. 2020;12(10):e10869.
Tleyjeh IM, Kashour Z, Damlaj M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(2):215-27.
Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020;79(10):1277-85.
Lin WT, Hung SH, Lai CC, et al. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021;96:107602.
Lan SH, Lai CC, Huang HT, et al. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(3):106103.
Zhao M, Lu J, Tang Y, et al. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies. Eur J Clin Pharmacol. 2021;77(3):311-9.
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970-5.
Leisman D, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. The Lancet Respiratory Medicine. 2020;8(12):1233-44.
Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med. 2020;8(12):1209-18.
Vaidya K, Oleksijew A, Tucker L, et al. A “Prozone-Like” effect influences the efficacy of the monoclonal antibody ABT-700 against the hepatocyte growth factor receptor. Pharmacology. 2017;100(5-6):229-42.
Casadevall A, Joyner MJ, Pirofski LA. Neutralizing antibody LY-CoV555 for outpatient COVID-19. NEJM. 2021;384(2):189.
U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. News release. Food and Drug Administration. 2021 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody bamlanivimab. (Accessed 19 April 2021).
Refbacks
- There are currently no refbacks.
This work is licensed under a